FATE

Fate Therapeutics, Inc. (FATE) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. The company has no approved products and generates revenue primarily through collaboration agreements and government grants. As of August 6, 2026, there were 119,820,514 shares of common stock issued and outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Collaboration revenue increased slightly for the three months ended June 30, 2026 ($2.1M) compared to the same period in 2025 ($1.9M). For the six-month period, revenue decreased slightly to $3.4M from $3.5M in 2025.
• Expenses: Total operating expenses decreased significantly. For the six months ended June 30, 2026, expenses were $67.5 million compared to $81.8 million in the prior year. This reduction was driven by a $7.5 million decrease in R&D expenses and a $6.8 million decrease in G&A expenses, largely due to reduced stock-based compensation and professional fees.
• Net Loss: The net loss improved to $(61.4) million for the six months ended June 30, 2026, compared to $(71.7) million in the prior year period.
• Liquidity: Cash, cash equivalents, and short-term investments decreased from $208.7 million (current assets total) at December 31, 2025, to $157.9 million at June 30, 2026, reflecting operating cash burn partially offset by investment maturities.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects that cash, cash equivalents, and short-term investments of $153.8 million as of June 30, 2026, will be sufficient to fund operations for at least the next twelve months.
• Development Progress:
  • FT819: Selected by the FDA for the Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) Program in May 2026 for the treatment of systemic lupus erythematosus (SLE). Received RMAT designation in April 2025.
  • FT839: Received FDA clearance in July 2026 to proceed with clinical research for this next-generation CAR T-cell product candidate targeting CD19 and CD38.
• Collaborations: The company continues its collaboration with Ono Pharmaceutical Co., Ltd. Performance obligations for research and preclinical development of Candidate 3 under the Ono Agreement were completed as of June 30, 2026.
• Risks:
  • Regulatory Uncertainty: Novel iPSC and gene-editing technologies face uncertain regulatory pathways. The FDA may require additional data or studies.
  • Manufacturing: Complex manufacturing processes for cell therapies pose risks regarding scale-up, consistency, and cost. The company relies on third-party suppliers for certain components.
  • Legal Proceedings: The company is defending against a securities class action lawsuit (Hadian v. Fate Therapeutics) and derivative actions regarding the termination of a prior collaboration with Janssen Biotech. Motions to dismiss have been granted with leave to amend, and the cases remain active.
  • Stock Price Milestones: The company has contingent milestone payment obligations to Memorial Sloan Kettering Cancer Center (MSKCC) totaling up to $75.0 million, dependent on stock price appreciation. A liability of $0.9 million was recorded as of June 30, 2026.

Investor Verification Checklist

• Verify the status of the FT819 Phase 1 study and the specific outcomes of the FDA CDRP Program participation.
• Confirm the timeline and enrollment status for the newly cleared FT839 clinical trial.
• Review the details of the Ono Pharmaceutical collaboration regarding the expiration of the Candidate 3 Development Option and future milestone triggers.
• Monitor the stock price appreciation milestone liability to MSKCC, as fluctuations in stock price directly impact this contingent liability.
• Assess the impact of ongoing securities litigation on management distraction and potential financial exposure.
• Validate the runway calculation of 12 months based on current cash burn rates and potential changes in clinical trial costs.